Researchers published a bioengineered viral system in Nature Communications that enables targeted RNA editing in macrophages in vivo using chemogenetic control. The platform demonstrated editing activity in animal models and delivered payloads to reprogram inflammatory macrophage responses, offering a potential therapeutic avenue for sepsis and other macrophage‑driven conditions. The team reported macrophage‑specific delivery and regulated editing, indicating translational potential for acute inflammatory diseases where immune cell reprogramming could alter outcomes. The study frames RNA editing delivered by engineered viral vectors as a pathway to cell‑type selective interventions inside living organisms.